Feb 12 (Reuters) - AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to impose price controls for ...
AbbVie has sued the Department of Health and Human Services (HHS), challenging the agency’s decision to select its blockbuster anti-wrinkle therapy Botox for the next round of Medicare price ...
The popular type 2 diabetes drug dulaglutide (Trulicity), botulinum toxin (Botox), and drugs to treat psoriatic arthritis, prostate cancer, and breast cancer are among the 15 drugs that the Centers ...
AbbVie says Congress excluded Botox from price controls Lawsuit alleges multiple constitutional violations Botox contributes over 10% to AbbVie's annual revenue HHS declines to comment Feb 12 (Reuters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results